TP53 and hematopoietic and lymphoid cell neoplasm: Because the codon distribution of TP53 mutations is not specific to the tissue origin of a cancer, therapy targeting the TP53 R175H epitope, for example, should be equally applicable in a TP53 R175H+ hematologic cancer as in a TP53 R175H+ solid tumor, assuming the epitope is processed and presented appropriately.